Volume 13, Number 11—November 2007
Dispatch
Human Multidrug-Resistant Salmonella Newport Infections, Wisconsin, 2003–2005
Table 1
Resistant to | Frequency (%) |
|
---|---|---|
Wisconsin (n = 268), 2003–2005 | Rest of United States (n = 402), 2003–2004 | |
None detected | 95 (35) | 317 (79) |
>1 CLSI subclass† | 173 (65) | 85 (21) |
>2 CLSI subclasses | 150 (56) | 81 (20) |
>3 CLSI subclasses | 150 (56) | 77 (19) |
>4 CLSI subclasses | 150 (56) | 74 (18) |
>5 CLSI subclasses | 146 (55) | 71 (18) |
At least ACSSuT‡ | 139 (52) | 69 (17) |
At least ACSuTm§ | 7 (3) | 4 (1) |
At least MDRAmpC¶ | 137 (51) | 68 (17) |
Quinolone and cephalosporin (third generation)# | 5 (2)** | 2 (0.5) |
*Based on data from the National Antimicrobial Resistance Monitoring System for Enteric Bacteria.
†CLSI, Clinical and Laboratory Standards Institute. Subclasses included aminoglycosides (kanamycin, gentamicin, streptomycin), aminopenicillins (ampicillin), β-lactamase inhibitor combinations (amoxicillin-clavulanic acid), first-generation cephalosporins (cephalothin), third-generation cephalosporins (ceftriaxone), cephamycins (cefoxitin), folate pathway inhibitors (trimethoprim-sulfamethoxazole), phenicols (chloramphenicol), quinolones (nalidixic acid, ciprofloxacin), sulfonamides (sulfisoxazole), and tetracyclines (tetracycline).
‡ACSSuT, ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline.
§ACSuTm, ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole.
¶At least drugs to which MDRAmpC is resistant: chloramphenicol, streptomycin, trimethoprim-sulfamethoxazole, sulfisoxazole, tetracycline, amoxicillin-clavulanic acid, ampicillin, cefoxitin, cephalothin, and ceftriaxone. Note: the Wisconsin State Laboratory of Hygiene does not routinely test Salmonella isolates for resistance to ceftiofur, a third-generation cephalosporin that is related to ceftriaxone.
#Resistant to ciprofloxacin and/or nalidixic acid, and ceftriaxone.
**1 isolate in this category was also MDRAmpC.